Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.37 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.37 |
| ▸ | DUT | P33316 | 2/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20347941 | 0.87 | TRPV1 (0.44) | ALDH1A1GAASCN8ASCN10ADUT | |
| SCHEMBL14118324 | 0.87 | SCN8A (0.46) | ALDH1A1GAASCN8ASCN10ADUT | |
| SCHEMBL20361809 | 0.84 | DUT (0.41) | ALDH1A1GAASCN8ASCN10ADUT | |
| SCHEMBL20361557 | 0.77 | PDE2A (0.39) | ALDH1A1GAASCN8ASCN10ADUT | |
| SCHEMBL24225596 | 0.76 | ALDH1A1 (0.44) | ALDH1A1GAAGRM2KDM1ATLR8 | |
| SCHEMBL13040799 | 0.76 | LMNA (0.39) | ALDH1A1 | |
| SCHEMBL1409593 | 0.76 | DUT (0.45) | DUTGRM2 | |
| SCHEMBL10289878 | 0.75 | ALDH1A1 (0.48) | ALDH1A1GAAGRM2KDM1ATLR8 | |
| SCHEMBL20351723 | 0.75 | SCN9A (0.43) | DUT | |
| SCHEMBL20347962 | 0.74 | ALDH1A1 (0.44) | ALDH1A1GAATRPV1AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11247984-B2 | Uracil containing compounds | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2022-02-15 | — | — | US | disclosed |
| US-11247984-B2 | Uracil containing compounds | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2022-02-15 | — | — | US | disclosed |
| US-20200039966-A1 | URACIL CONTAINING COMPOUNDS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2020-02-06 | — | — | US | disclosed |
| US-20200039966-A1 | URACIL CONTAINING COMPOUNDS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2020-02-06 | — | — | US | disclosed |
| WO-2018128720-A1 | URACIL CONTAINING COMPOUNDS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039966-A1 | URACIL CONTAINING COMPOUNDS | UNG, DPYD, DUT | ALDH1A1 970/4885GAA 340/4885SCN8A 4595/4885 |
| US-11247984-B2 | Uracil containing compounds | UNG, DPYD, DUT | ALDH1A1 970/4885GAA 340/4885SCN8A 4595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.